Sangui BioTech International Inc., US80105B1017

Sangui BioTech International Inc., US80105B1017

01.11.2016 - 16:07:26

Sangui BioTech International Inc.: * SastoMed enters into sales agreements for Southeast Asia, Poland and Russia; Firm purchase commitments agreed

Sangui BioTech: - SastoMed enters into sales agreements for Southeast Asia, Poland and Russia

- Firm purchase commitments agreed

Witten - November 01, 2016

SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, concluded a comprehensive licensing and sales agreement for eight Southeast Asian States with Zuellig Pharma, Singapure (www.zuelligpharma.com) one of the world's leading service providers of the pharmaceuticals. Zuellig Pharma is responsible for market launch and distribution of Granulox in the territories of HongKong, Singapore, Thailand, Malaysia, Taiwan, Vietnam, Indonesia and the Philippines. In addition to the complete processing and financing of admission in the individual territories, Zuellig Pharma has committed itself to the purchase of significant quantities of Granulox within the next five years. Furthermore, two high - performance distribution partners could be bound: Hexanova Sp.z.o.o. for Poland (www.hexanova.pl) and MDP Group for Russia (www.mdp-group.net). In both cases, minimum purchase commitments were also been agreed upon.

"With these agreements, we have succeeded in pushing forward into new dimensions. Inside the newly acquired sales areas, more than half a billion people live. We have now reached an important milestone on our path to global expansion. In addition to the quantitative dimension, the qualitative contract value of the agreements was also increased. In the past five years, Granulox has proven in field that it keeps what it promises on paper. When granting new territories, we now benefit from the appreciation Granulox has now gained. For instance, Zuellig Pharma for Southeast Asia and the MDP Group for Russia, two veritable global players with a corresponding sales force and financial strength, could be obtained for Granulox. Both partners have committed themselves to realize the necessary regulatory approvals and subsequent market launch of Granulox in the respective territories. Guaranteed purchase commitments were agreed with both partners. The annual minimum purchase quantities fixed within the next five-year period up to 2021 are based on the time-staggered progress of the product launches expected by Zuellig Pharma and MDP Group. Starting with the approval of Granulox, followed by the starts of the marketing campaigns and Granulox's positive sales development, specific verifiable milestones were established together with our partners for the individual territories. The cumulative purchase commitments for quantities over the next five years are well in the middle six-digit range. On the one hand, this minimum order gives us further planning certainty and ensures that we achieve our ambitious goals. On the other hand, this fact underscores the strong confidence our partners have in the future success of the cooperation with SastoMed ", explains Michael Sander, CEO of Sastomed GmbH.

"We congratulate SastoMed on these breakthroughs. After the inclusion of Granulox in the Drug Tariff of the British NHS at the beginning of October 2016, SastoMed herewith has reached further trend-setting successes. Sangui as licensors for Granulox will definitively benefit from these success. In this regard, the year 2016 can be described as very successful ", says Thomas Striepe, President and CEO of Sangui BioTech International Inc.

Sangui BioTech International, Inc. ("SGBI") ist eine Holding-Gesellschaft, deren Aktien auf OTCQB (www.otcmarkets.com: SGBI) und im Freiverkehr der Börsen Berlin und Hamburg-Hannover (www.boersenag.de: SBH) gehandelt werden. Ihr Geschäftszweck ist die Mittelbeschaffung und die Sicherung des Zugangs zum Kapitalmarkt für die Unternehmen der Sangui-Gruppe. SanguiBioTech GmbH ist eine neunzigprozentige Tochtergesellschaft der Sangui Biotech International, Inc.

Weitere Informationen: Thomas Striepe Sangui Biotech International, Inc. Fax: +49 (2302) 915 191 E-Mail: info@sangui.de Einige Aussagen in dieser Mitteilung betreffen Erwartungen für die Zukunft, enthalten Schätzungen künftiger Betriebsergebnisse oder finanzieller Umstände oder machen andere in die Zukunft gerichtete Feststellungen. Ob diese Aussagen sich bewahrheiten, hängt von vielen bekannten Risiken, unerwarteten Entwicklungen, Unsicherheiten oder anderen Faktoren ab, die dazu führen können, dass die künftig tatsächlich eintretende Entwicklung von diesen Zukunftserwartungen wesentlich abweicht. Die in die Zukunft gerichteten Aussagen basieren auf einer Vielzahl von Variablen und Annahmen. Zu der Vielzahl wichtiger Risiken, die zu Abweichungen von den hier getroffenen Aussagen führen können, gehört unter anderem, aber nicht ausschließlich, die Fähigkeit des Unternehmens, hinreichende Finanzmittel für die künftige Geschäftstätigkeit zu erlangen. Wörter wie "glauben", "schätzen", "planen", "erwarten", "beabsichtigen" oder "vorhersagen", andere Formen dieser Wörter oder vergleichbare Ausdrücke sollen erkennen lassen, dass es sich um in die Zukunft gerichtete Aussagen handelt. Das Unternehmen übernimmt keine über die gesetzlichen Bestimmungen hinausgehende Verpflichtung, die hier getroffenen Aussagen zu korrigieren oder an veränderte Bedingungen und Entwicklungen anzupassen.

01.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

516339 01.11.2016

@ dgap.de